1. Home
  2. SGMT vs PMM Comparison

SGMT vs PMM Comparison

Compare SGMT & PMM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SGMT
  • PMM
  • Stock Information
  • Founded
  • SGMT 2006
  • PMM 1989
  • Country
  • SGMT United States
  • PMM United States
  • Employees
  • SGMT N/A
  • PMM N/A
  • Industry
  • SGMT
  • PMM Investment Managers
  • Sector
  • SGMT
  • PMM Finance
  • Exchange
  • SGMT Nasdaq
  • PMM Nasdaq
  • Market Cap
  • SGMT 230.3M
  • PMM 251.7M
  • IPO Year
  • SGMT 2023
  • PMM N/A
  • Fundamental
  • Price
  • SGMT $7.11
  • PMM $5.97
  • Analyst Decision
  • SGMT Strong Buy
  • PMM
  • Analyst Count
  • SGMT 7
  • PMM 0
  • Target Price
  • SGMT $26.57
  • PMM N/A
  • AVG Volume (30 Days)
  • SGMT 601.4K
  • PMM 118.3K
  • Earning Date
  • SGMT 08-13-2025
  • PMM 01-01-0001
  • Dividend Yield
  • SGMT N/A
  • PMM 4.68%
  • EPS Growth
  • SGMT N/A
  • PMM N/A
  • EPS
  • SGMT N/A
  • PMM 0.23
  • Revenue
  • SGMT N/A
  • PMM N/A
  • Revenue This Year
  • SGMT N/A
  • PMM N/A
  • Revenue Next Year
  • SGMT N/A
  • PMM N/A
  • P/E Ratio
  • SGMT N/A
  • PMM $26.52
  • Revenue Growth
  • SGMT N/A
  • PMM N/A
  • 52 Week Low
  • SGMT $1.73
  • PMM $5.00
  • 52 Week High
  • SGMT $11.41
  • PMM $6.42
  • Technical
  • Relative Strength Index (RSI)
  • SGMT 39.46
  • PMM 64.03
  • Support Level
  • SGMT $7.01
  • PMM $5.80
  • Resistance Level
  • SGMT $7.68
  • PMM $5.87
  • Average True Range (ATR)
  • SGMT 0.51
  • PMM 0.05
  • MACD
  • SGMT -0.02
  • PMM 0.01
  • Stochastic Oscillator
  • SGMT 39.03
  • PMM 100.00

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

About PMM Putnam Managed Municipal Income Trust

Putnam Managed Municipal Income Trust is a closed-end management investment company. Its investment objective is to seek a high level of current income exempt from federal income tax by investing in a diversified portfolio of tax-exempt municipal securities. The Fund invests in various sectors such as healthcare, retirement community, private higher education, housing-backed, essential service utilities, and state-backed bonds.

Share on Social Networks: